Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics: Two directors Nicholson and Gruia resign from board effective Oct. 13, 2026

Neutral Impact 2 of 5 leadership Written later

TScan Therapeutics disclosed that directors Garry Nicholson and Gabriela Gruia, M.D., resigned from its Board of Directors and all board committees, effective October 13, 2026, with no disagreement with the company cited. The board filled the vacancies on its committees, appointing Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee, which matters to shareholders as a change in board composition and committee makeup.

Key points

  • Garry Nicholson and Gabriela Gruia, M.D., resigned from the board and all committees effective October 13, 2026.
  • The filing states the resignations were not due to any disagreement with the company on operations, practices or policies.
  • Stephen Biggar (member) and R. Keith Woods (chairperson) were appointed to the Nominating and Corporate Governance Committee effective October 13, 2026.
  • The Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.

The filing

CompanyTScan Therapeutics, Inc. (TCRX)
Form8-K, current report
Filed with the SECOct 16, 2026, 4:45 PM ET
Accession number0001193125-26-424198

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.